GlassScriptPhysician profile
Paul Gradolph
NPI 1417946815
$2,305.31
in general payments reported to CMS, 2019-2025
25 companies · $19.55 in 2025
The $19.55 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,554 · 2020: $534 · 2021: $165 · 2022: $32.55 · 2025: $19.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $380.41 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.74 | 2019-2021 | |
| Pfizer INC. | $215.35 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $197.12 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.15 | 2019-2020 | |
| Glaxosmithkline, LLC. | $165.92 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $122.91 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $122.19 | 2019-2020 | |
| Amarin Pharma, INC. | $89.24 | 2019-2020 | |
| Novo Nordisk INC | $74.91 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.53 | 2019 | |
| Astellas Pharma US INC | $57.62 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $45.84 | 2021 | |
| Lilly USA, LLC | $40.46 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $36.20 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $36.00 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $29.00 | 2019 | |
| Radius Health, INC. | $25.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $25.05 | 2019 | |
| Allergan, INC. | $19.59 | 2019 | |
| Exact Sciences Corporation | $19.55 | 2025 | The Cologuard Plus Collection Kit |
| Bausch Health US, LLC | $18.55 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.27 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.38 | 2020 | |
| Abbvie INC. | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Gradolph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.